Inotek Pharmaceuticals is a privately held and funded biotechnology company focused on the discovery and development of innovative drugs to address serious diseases of the eye. Inotek scientists have discovered drug candidates with the potential to ameliorate ischemia-reperfusion injury, oxidative stress, and neuropathy, key targets for drugs to treat Age-related Macular Degeneration, Glaucoma and Retinal Neuropathies.
The Company's lead program, trabodenoson (INO-8875) is a highly selective adenosine mimetic that targets the A1 sub-receptor. Its novel and elegant mechanism of action provides a new approach to lowering IOP that augments the natural process that healthy eyes use to allow excess fluid to drain from the eye through the trabecular meshwork. This mechanism would make trabodenoson, if ultimately approved by health authorities, a valuable tool that ophthalmologists could use - alone or in conjunction with any of the available medicines - to treat open-angle glaucoma and ocular hypertension. Trabodenoson has completed Phase 1 and Phase 2 clinical trials and is currently being evaluated in a multiple-dose late Phase 2 trial. In the completed clinical trials, trabodenoson significantly reduced intraocular pressure (IOP) and was well tolerated in patients with glaucoma or ocular hypertension.
Inotek has an experienced management team with a track record of multiple successful NDAs to advance the Company's clinical programs towards commercialization so they can benefit patients and the physicians that help manage their ocular disease. The Company is based in Lexington, MA